Colchicine Dosing Guidelines for Familial Mediterranean Fever

Age-Based Dosing Algorithm

• The European League Against Rheumatism (EULAR) guidelines recommend a starting dose of colchicine for children <5 years as ≤0.5 mg/day, for children 5-10 years as 0.5-1.0 mg/day, and for children >10 years and adults as 1.0-1.5 mg/day 1, 3, 4, 5
• For a 63 kg patient with fever syndrome, the starting dose of colchicine is 1.0-1.5 mg/day, as this patient's weight places them in the adult/adolescent category (>10 years of age) 1, 2

Practical Dosing Considerations

• The dose can be given once daily or divided into two doses depending on gastrointestinal tolerance, with the option to start at the lower end of the range (1.0 mg/day) if concerned about tolerance, then titrate upward based on response 6, 7, 8, 3
• Starting at a lower dose and increasing gradually is preferred by most experts, according to the EULAR guidelines 6, 3

Dose Escalation Strategy

• If attacks persist or subclinical inflammation continues, increase the dose by 0.5 mg increments no more frequently than weekly, with a maximum dose of 2 mg/day in children and 3 mg/day in adults, as recommended by the EULAR guidelines 2, 5
• Monitor CRP and/or serum amyloid A (SAA) protein at least every 3 months during dose escalation to determine the necessary colchicine dose, according to the EULAR guidelines 3, 4

Important Caveats

• Patients with pre-existing complications or greater disease activity may require initiation at higher doses within the recommended range, according to the EULAR guidelines 6, 3
• For patients who develop gastrointestinal intolerance, consider starting at a subtherapeutic dose of 0.5 mg/day and increasing gradually by 0.5 mg increments, as recommended by the EULAR guidelines 6, 7

Monitoring Requirements

• Follow patients closely for 3-6 months after starting colchicine to observe therapeutic effect on attack frequency and severity, with regular visits every 3-6 months once stable, according to the EULAR guidelines 6, 3, 1, 2
• Monitor liver enzymes regularly, and if elevated greater than twofold the upper limit of normal, reduce colchicine dose and investigate the cause, as recommended by the EULAR guidelines 4

Definition of Treatment Failure

• Colchicine resistance is defined as ≥1 attack per month over a 3-month period despite maximum tolerated dose, or persistent laboratory inflammation between attacks, according to the EULAR guidelines 2, 5
• In cases of colchicine resistance, consider adding IL-1 inhibitors (anakinra, canakinumab, or rilonacept) as second-line therapy, as recommended by the EULAR guidelines 1, 2